INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
07.08.26 | 15:25
1,420 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,460 | 1,530 | 07.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.07. | Innate Pharma SA: Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference | 367 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 21.07. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.07. | Innate Pharma schließt Patientenrekrutierung für Phase-1-Studie zu IPH4502 ab | 1 | Investing.com Deutsch | ||
| 21.07. | Innate Pharma completes enrollment in IPH4502 phase 1 study | 1 | Investing.com | ||
| 21.07. | Innate Pharma SA: Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC) | 311 | Business Wire | Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end Favorable safety profile observed to date, with limited... ► Artikel lesen | |
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 22.05. | Innate Pharma SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.05. | Innate Pharma SA: Outcome of Innate Pharma's 2026 Annual General Meeting | 425 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took... ► Artikel lesen | |
| 19.05. | Innate Pharma SA: Innate Pharma to participate in the Jefferies Global Healthcare Conference | 497 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 16.05. | Innate Pharma übertrifft Erwartungen - Aktie steigt vorbörslich um fast 60 % | 4 | Investing.com Deutsch | ||
| 13.05. | Innate Pharma SA - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 13.05. | Innate Pharma reports Q1 results | 8 | Seeking Alpha | ||
| 13.05. | Innate Pharma SA: Innate Pharma Reports First Quarter 2026 Business Update and Financial Results | 699 | Business Wire | Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation... ► Artikel lesen | |
| 12.05. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026 | 366 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 06.05. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.05. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update | 421 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30... ► Artikel lesen | |
| 23.04. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | Innate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global Conference | 375 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 17.04. | Innate Pharma legt Zwischenergebnisse zu Lungenkrebsstudie vor | 1 | Investing.com Deutsch | ||
| 17.04. | Innate Pharma reports interim lung cancer trial results | 1 | Investing.com | ||
| 17.04. | Innate Pharma SA: Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 | 604 | Business Wire | Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVORYON THERAPEUTICS | 1,235 | +0,41 % | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
Strategic partnering remains a key priority, with multiple strategic discussions progressing, including... ► Artikel lesen | |
| TME PHARMA | 0,057 | 0,00 % | TME Pharma NV: Minutes of the TME Pharma Annual General Meeting | Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| CANSINO BIOLOGICS | 2,700 | +0,75 % | CanSino Biologics Inc: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South America | HONG KONG, June 29, 2026 - (ACN Newswire) - On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)... ► Artikel lesen | |
| KARYOPHARM | 1,740 | -4,40 % | Karyopharm Therapeutics Inc.: Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer | - The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) -
- A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement... ► Artikel lesen | |
| ADICET BIO | 7,100 | +2,90 % | Adicet Bio, Inc. - 8-K, Current Report | ||
| MEREO BIOPHARMA | 0,254 | -1,55 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen | |
| ANNOVIS BIO | 1,638 | +0,99 % | Annovis Bio Inc.: Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer | MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy... ► Artikel lesen | |
| INTEGRA LIFESCIENCES | 14,900 | 0,00 % | Integra LifeSciences Holdings Corporation: Integra LifeSciences Reports Second Quarter 2026 Financial Results | PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second... ► Artikel lesen | |
| RHYTHM PHARMACEUTICALS | 100,00 | 0,00 % | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity | -- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon -- -- Management to host conference call to discuss second quarter... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 3,855 | +0,92 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| RECCE PHARMACEUTICALS | 0,260 | -0,76 % | RECCE PHARMACEUTICALS LTD: Change of Director's Interest Notices (x4) | ||
| MABION | 1,658 | -0,24 % | Mabion Enters Rare Disease Collaboration with Oddifact | ||
| APOGEE THERAPEUTICS | 134,84 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,390 | 0,00 % | If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.